Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
26
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

494
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
494
Hepatic Drug Clearance: Role of Transporters01:14

Hepatic Drug Clearance: Role of Transporters

34
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
34
Pore Transport and Ion-Pair Transport01:17

Pore Transport and Ion-Pair Transport

350
Pore transport and ion-pair formation are critical mechanisms for the absorption and distribution of drugs in the body.
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited  but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
350
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

247
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
247
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

100
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
100

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the Utility and Constraints of the Competitive Counter Flow (CCF) Assay in OATP1B1 Substrate Profiling.

The AAPS journal·2026
Same author

Predicting human pharmacokinetic parameters of drugs using a multi-tissue chip platform integrating liver, kidney, and skeletal muscle microphysiological systems.

Lab on a chip·2026
Same author

Advances in DDI evaluations: Recent trends from pre-clinical studies to regulatory submissions.

Drug metabolism and pharmacokinetics·2026
Same author

Biodistribution of Cerivastatin, Repaglinide, Glyburide, Rosuvastatin, and Valsartan in Cynomolgus Monkeys and PBPK Analysis.

The AAPS journal·2026
Same author

Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvir.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Cytochrome P450 reaction phenotyping: State of the art.

Drug metabolism and pharmacokinetics·2026

Related Experiment Video

Updated: Jun 3, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K

Positioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug Design.

Thomas Schroeter1, Kimberly Lapham1, Manthena V S Varma1

  • 1Department of Pharmacokinetics Dynamics & Metabolism, Pfizer Inc., Groton, Connecticut 06340, United States.

Journal of Medicinal Chemistry
|January 6, 2025
PubMed
Summary

Drug development can streamline early assessments of drug-drug interactions (DDIs) by focusing on key enzymes and transporters. This approach helps prioritize candidates addressing unmet medical needs without compromising safety.

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

46.2K

Related Experiment Videos

Last Updated: Jun 3, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.3K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

46.2K

Area of Science:

  • Pharmacology
  • Drug Discovery
  • Medicinal Chemistry

Background:

  • * In vitro assessment of drug-drug interactions (DDIs) is crucial in drug research.
  • * Regulatory bodies mandate extensive testing, but not all interactions significantly impact clinical outcomes.
  • * Prioritizing drug candidates for unmet medical needs requires efficient DDI risk management.

Purpose of the Study:

  • * To define simplified criteria and high-throughput methodologies for assessing DDI risk.
  • * To enable early-stage drug design strategies that mitigate DDI potential.
  • * To focus on critical drug-metabolizing enzymes and transporters.

Main Methods:

  • * Development of simplified criteria for DDI risk assessment.
  • * Implementation of high-throughput screening methodologies.
  • * Focused strategy on key enzymes: cytochrome P450 (CYP) 3A4, CYP2C9, CYP2D6.
  • * Focused strategy on key transporters: organic anion transporting polypeptide (OATP) 1B1, breast cancer resistant protein (BCRP).

Main Results:

  • * Defined simplified criteria and methodologies for DDI risk assessment.
  • * Proposed a focused strategy for drug design to address DDI risk.
  • * Identified key enzymes and transporters for prioritized screening.

Conclusions:

  • * Streamlined DDI assessment can facilitate drug development for unmet needs.
  • * Focusing on critical enzymes (CYP3A4, CYP2C9, CYP2D6) and transporters (OATP1B1, BCRP) optimizes DDI risk management.
  • * Early drug design incorporating these principles can reduce clinical DDI issues.